The biosensors were further applied to the signaling profiling and pharmacological characterization of various activating mutations frequently found in GBM: EGFR-vIII (N-terminal deletion mutant lacking exons 2–7), EGFR-vIV (C-terminal deletion mutant lacking exons 25–27) and the extracellular point mutant EGFR-G598V34,60. This evidence concerns the gene EGFR and glioblastoma.